Education
About Us
Working with TipRanks
Follow Us
Applied Therapeutics Inc (APLT)
NASDAQ:APLT
APLT Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.30 - $10.62
Previous CloseN/A
Volume3.84M
Average Volume (3M)2.01M
Market Cap
$43.24M
Enterprise Value$1.13B
Total Cash (Recent Filing)-$3.28M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.38
Next Earnings
May 08, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.52
Shares Outstanding116,356,476
10 Day Avg. Volume2,705,103
30 Day Avg. Volume2,006,528
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)6.67
Price to Cash Flow (P/CF)-0.70
P/FCF Ratio0.00
Enterprise Value/Market Cap26.14
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit2.48K
Enterprise Value/Ebitda-12.26
Forecast
1Y Price Target
$2.25Price Target Upside581.82% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
---
Applied Therapeutics News
PremiumCompany Announcements
Applied Therapeutics Reports 2024 Financial Results and Leadership Changes
PremiumCompany Announcements
Applied Therapeutics Delays Yearly Report Filing
---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe clinical trial in SORD met its co-primary endpoints, suggesting a potentially stronger data package.
Community SupportGovorestat still has a lot of support from the galactosemia KOL community and patient advocates, highlighting the unmet need.
Management ChangesThe strengthening of Applied's management team is a key step in rebuilding the company's reputation and regulatory readiness.
Bears Say
Financial RisksThe company is seen as bearing increased financial risk given its limited cash runway.
Regulatory ChallengesAPLT received a Complete Response Letter for govorestat in classic galactosemia, which comes as a major surprise, given the progress the company appeared to be making with the FDA.
Regulatory DelaysThe recent FDA turnover and uncertainty on the timeline for FDA alignment have led to a push back of the launch of govorestat in galactosemia and SORD deficiency to the third quarter of 2026 in the model.
---
Ownership Overview
15.00% Insiders
10.34% Mutual Funds
0.26% Other Institutional Investors
59.11% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
APLT FAQ
What was Applied Therapeutics Inc’s price range in the past 12 months?
Applied Therapeutics Inc lowest stock price was $0.30 and its highest was $10.62 in the past 12 months.
What is Applied Therapeutics Inc’s market cap?
Applied Therapeutics Inc’s market cap is $43.24M.
When is Applied Therapeutics Inc’s upcoming earnings report date?
Applied Therapeutics Inc’s upcoming earnings report date is May 08, 2025 which is in 15 days.
How were Applied Therapeutics Inc’s earnings last quarter?
Applied Therapeutics Inc released its earnings results on Apr 14, 2025. The company reported $0.52 earnings per share for the quarter, beating the consensus estimate of -$0.182 by $0.702.
Is Applied Therapeutics Inc overvalued?
According to Wall Street analysts Applied Therapeutics Inc’s price is currently Undervalued.
Does Applied Therapeutics Inc pay dividends?
Applied Therapeutics Inc does not currently pay dividends.
What is Applied Therapeutics Inc’s EPS estimate?
Applied Therapeutics Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Applied Therapeutics Inc have?
Applied Therapeutics Inc has 116,356,476 shares outstanding.
What happened to Applied Therapeutics Inc’s price movement after its last earnings report?
Applied Therapeutics Inc reported an EPS of $0.52 in its last earnings report, beating expectations of -$0.182. Following the earnings report the stock price went down -10.811%.
Which hedge fund is a major shareholder of Applied Therapeutics Inc?
Currently, no hedge funds are holding shares in APLT
---
Applied Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$2.25 (581.82% Upside)
$2.25 (581.82% Upside)
Blogger Sentiment
Bullish
APLT Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 7.1M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $94.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 1.5%
Last 30 Days ▼ 1.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-93.05%
12-Months-Change
Fundamentals
Return on Equity
-3179.06%
Trailing 12-Months
Asset Growth
135.79%
Trailing 12-Months
Company Description
Applied Therapeutics Inc
Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that has completed phase 1/2 for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study for the treatment of galactosemia in kids; for treating sorbitol dehydrogenase deficiency; and for the treatment of phosphomannomutase enzyme-CDG. The company also develops AT-001 that is in phase III clinical trials for treating diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy. Its preclinical stage products include AT-003 for the treatment diabetic retinopathy; AT-104, a PI3K inhibitor for treating orphan hematological oncology T Cell Acute Lymphoblastic Leukemia. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.
---
APLT Stock 12 Month Forecast
Average Price Target
$2.25
▲(581.82% Upside)
Technical Analysis
Agenus
―
CytomX Therapeutics
―
Fortress Biotech
―
Skye Bioscience
―
Immix Biopharma, Inc.
―
Best Analysts Covering APLT
1 Year
1 Year Success Rate
11/32 ratings generated profit
1 Year Average Return
+55.46%
reiterated a buy rating 5 months ago
Copying Brian Skorney's trades and holding each position for 1 Year would result in 34.38% of your transactions generating a profit, with an average return of +55.46% per trade.
---